glucagon has been researched along with incretins in 164 studies
Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (incretins) | Trials (incretins) | Recent Studies (post-2010) (incretins) |
---|---|---|---|---|---|
26,039 | 1,498 | 3,054 | 2,373 | 249 | 1,914 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 18 (10.98) | 29.6817 |
2010's | 115 (70.12) | 24.3611 |
2020's | 31 (18.90) | 2.80 |
Authors | Studies |
---|---|
Holst, JJ; Højberg, PV; Knop, FK; Krarup, T; Larsen, S; Madsbad, S; Vilsbøll, T | 1 |
Cassidy, RS; Flatt, PR; Gault, VA; Holst, JJ; Irwin, N; McClean, PL | 1 |
Baz-Hecht, M; Bernier, R; Devine, E; Goldfine, AB; Holst, JJ; Jones, DB; Mun, EC; Patti, ME; Schneider, BE | 1 |
McIntosh, CH | 1 |
Baller, B; Ellrichmann, M; Holst, JJ; Meier, JJ; Nauck, MA; Schmidt, WE; Vollmer, K | 1 |
Bawa, B; Colarusso, A; Egger, JR; Koshy, N; Kovack, B; Laferrère, B; Lee, H; McGinty, J; Olivan, B; Teixeira, J; Tran, H; Yapp, K | 1 |
Ahrén, B; Carr, RD; Deacon, CF; Jelic, K; Larsen, MO; Lindgren, O; Winzell, MS | 1 |
Debaty, I; Halimi, S; Muller, M; Villaret, L | 1 |
Hoist, JJ; Lasalle, JR | 1 |
Girard, J | 1 |
Bianchi, C; Gentilella, R; Rossi, A; Rotella, CM | 1 |
Pratley, RE | 1 |
Ahrén, B; Carr, RD; Deacon, CF; Lindgren, O; Mari, A; Vikman, J; Winzell, MS | 1 |
Besanko, LK; Burgstad, CM; Chapman, MJ; Deane, AM; Fraser, RJ; Horowitz, M | 1 |
Astrup, A; Brader, L; de Vrese, M; Hermansen, K; Holm, L; Holst, JJ; Mortensen, L; Schrezenmeir, J; Thomsen, C | 1 |
Gandhi, GY; Kovalaske, MA | 1 |
Beglinger, C; Castelli, MC; Drewe, J; Friedman, K; Huber, AR; Poller, B; Steinert, RE | 1 |
Gallwitz, B; Thornberry, NA | 1 |
Dirksen, C; Hansen, DL; Holst, JJ; Hvolris, LE; Madsbad, S; Naver, LS; Worm, D | 1 |
Luft, FC | 1 |
Diamant, M; van Genugten, RE; van Raalte, DH | 1 |
Bagger, JI; Hansen, KB; Holst, JJ; Knop, FK; Vilsbøll, T | 2 |
Deacon, CF; Holst, JJ; Jacob, A; Meier, JJ; Menge, BA; Nauck, MA; Ritter, PR; Schmidt, WE | 1 |
Bellon, M; Fraser, RJ; Holloway, RH; Horowitz, M; Jones, KL; Kuo, P; Rayner, CK; Smout, AJ; Wishart, JM | 1 |
Degerblad, M; Edholm, T; Efendic, S; Grybäck, P; Hellström, PM; Hilsted, L; Holst, JJ; Jacobsson, H; Schmidt, PT | 1 |
Svec, F | 1 |
Arias, S; Bawa, B; Bose, M; Laferrère, B; Machineni, S; Olivan, B; Pi-Sunyer, FX; Scherer, PE; Teixeira, J | 1 |
Garber, AJ | 1 |
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 4 |
Asmar, M | 1 |
Sandoval, DA; Tong, J | 1 |
Bagger, JI; Holst, JJ; Knop, FK; Lund, A; Vilsbøll, T | 1 |
Chapman, I; Greville, H; Hetzel, D; Horowitz, M; Jones, KL; Kuo, P; Maddox, A; Rayner, CK; Russo, A; Stevens, JE; Wishart, JM | 1 |
Ali, S; Charron, MJ; Drucker, DJ; Lamont, BJ | 1 |
Damm, P; Nolan, CJ; Prentki, M | 1 |
Irwin, DM; Prentice, KJ | 1 |
Christensen, M; de Heer, J; Holst, JJ; Kielgast, U; Knop, FK; Lund, A; Svendsen, B | 1 |
Aaboe, K; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T; Vølund, A | 1 |
Kishimoto, M; Noda, M | 1 |
Gjedsted, J; Juhl, CB; Nielsen, MF; Schmitz, O | 1 |
Allister, EM; Bhattacharjee, A; Wheeler, MB | 1 |
Carneiro, L; Derani, A; Göke, B; Schirra, J; Woerle, HJ | 1 |
Castagneto-Gissey, L; Mingrone, G | 1 |
Færch, K; Hansen, T; Holst, JJ; Jørgensen, T; Knop, FK; Pedersen, O; Pilgaard, K | 1 |
Cao, X; Drucker, DJ; Flock, GB; Maziarz, M | 1 |
Deacon, CF; Diamant, M; Heine, RJ; Holst, JJ; Karemaker, JM; Kwa, KA; Mari, A; Tushuizen, ME; van Genugten, RE; van Raalte, DH | 1 |
Aoki, K; Kamiyama, H; Masuda, K; Terauchi, Y; Togashi, Y | 1 |
Chen, C; Chen, Z; Han, Y; Shen, J; Zhu, X | 1 |
Feldt-Rasmussen, B; Holst, JJ; Hornum, M; Idorn, T; Jørgensen, M; Knop, FK | 2 |
Coester, HV; Forst, T; Hincelin-Méry, A; Kapitza, C; Poitiers, F; Ruus, P | 1 |
Cho, YM; Kim, MY; Kim, S; Lee, JC; Oh, TJ; Park, KS; Shin, JY | 1 |
Chang, J; Greenfield, JR; Horowitz, M; Rayner, CK; Samocha-Bonet, D; Wu, T | 1 |
Blaak, EE; Holst, JJ; Knop, FK; Konings, E; Schrauwen, P; Timmers, S | 1 |
Alssema, M; Dekker, JM; Eekhoff, EM; Gastaldelli, A; Hart, LM; Holst, JJ; Mari, A; Nijpels, G; Rijkelijkhuizen, JM; Scheffer, PG; Teerlink, T | 1 |
Anděl, M; Červinková, Z; Fontana, J | 1 |
Borgoño, CA; Kramer, CK; Retnakaran, R; Van Nostrand, P; Zinman, B | 1 |
Aoki, K; Honda, K; Kamisoyama, H; Nakanishi, K; Saneyasu, T; Shimatani, T; Yamaguchi, T | 1 |
Calanna, S; Di Pino, A; Knop, FK; Piro, S; Purrello, F; Rabuazzo, AM; Scicali, R | 1 |
Aylor, KW; Basu, A; Chai, W; Fowler, DE; Jahn, LA; Liu, Z; Sauder, MA; Subaran, SC | 1 |
Couper, JJ; Horowitz, M; Kritas, S; Martin, AJ; Perano, SJ; Rayner, CK; Sullivan, T | 1 |
Bagger, JI; Hansen, T; Holst, JJ; Knop, FK; Pedersen, O; Vilsbøll, T; Østoft, SH | 1 |
Bound, M; Checklin, H; Horowitz, M; Jones, KL; Lange, K; Marathe, CS; Rayner, CK; Standfield, S; Wishart, J | 1 |
Abroun, S; Allahverdi, A; Jafarian, A; Pourpak, Z; Soleimani, M; Taghikhani, M | 1 |
Holmes, D | 1 |
de Oliveira, Mda S; Geloneze, B; Novaes, FS; Pareja, JC; Tambascia, MA; Vasques, AC | 1 |
Aulinger, BA; D'Alessio, DA; Drazen, DL; Seeley, RJ; Smith, EP; Ulrich-Lai, Y; Vahl, TP; Woods, SC | 1 |
Pellitero, S; Puig-Domingo, M | 1 |
Abdulla, H; Atherton, PJ; Idris, I; Phillips, B; Smith, K; Wilkinson, D | 1 |
Deng, Y; Gu, W; Gu, Y; Hong, J; Liu, T; Ning, G; Shi, J; Sun, Z; Wang, C; Wang, W; Yao, S; Zhang, Y; Zheng, S | 1 |
Abuaysheh, S; Batra, M; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Green, K; Makdissi, A; Patel, R | 1 |
Katsuno, T; Kusunoki, Y; Matsuo, T; Miuchi, M; Miyagawa, J; Murai, K; Namba, M; Ochi, F; Tokuda, M | 1 |
Bambrick, JE; Chia, B; Deane, AM; Debreceni, TL; Horowitz, M; Nguyen, NQ; Rayner, CK; Wishart, J; Young, RL | 1 |
Escalada, FJ | 1 |
Bräuner-Osborne, H; Iversen, H; Knudsen, SM; Nøhr, AC; Roed, SN; Waldhoer, M; Wismann, P | 1 |
Ahrén, B; Deacon, CF; Holst, JJ; Lindgren, O; Pacini, G; Tura, A | 1 |
Deacon, CF; Hamamoto, Y; Hamasaki, A; Harada, N; Hirano, T; Holst, JJ; Inagaki, N; Iwasaki, M; Kuroe, A; Kurose, T; Lee, S; Murotani, K; Seino, Y; Watanabe, K; Yabe, D; Yamane, S | 1 |
Ackermans, MT; de Sonnaville, JJJ; Frier, BM; Hartmann, B; Hoekstra, JBL; Holleman, F; Holst, JJ; Knop, FK; Schopman, JE; Stades, AM; Zwertbroek, R | 1 |
Cho, WK; Jung, MH; Park, MS; Park, SH; Suh, BK | 1 |
Bagger, JI; Hansen, T; Hartmann, B; Holst, JJ; Knop, FK; Pedersen, O; Vilsbøll, T; Østoft, SH | 1 |
Bindels, LB; Burkart, V; Hartmann, B; Henrich, B; Holst, JJ; Hwang, JH; Kolb, H; MacKenzie, C; Martinez, I; Nowotny, B; Nowotny, P; Pacini, G; Roden, M; Schloot, NC; Simon, MC; Stehle, P; Strassburger, K; Walter, J; Zivehe, F | 1 |
Gyldenløve, M; Holst, JJ; Knop, FK; Skov, L; Vilsbøll, T; Zachariae, C | 1 |
Heden, TD; Kanaley, JA; Leidy, HJ; Nyhoff, LM; Park, YM; Thyfault, JP; Winn, NC | 1 |
Craft, D; Warunek, D; Yi, J | 1 |
Deacon, CF; Eelderink, C; Holst, JJ; Koehorst, M; Noort, MW; Oudhuis, L; Poutanen, K; Priebe, MG; Rehfeld, JF; Sozer, N; Vonk, RJ | 1 |
Østoft, SH | 1 |
Ahrén, B; Alsalim, W; Bizzotto, R; Mari, A; Omar, B; Pacini, G; Tura, A | 1 |
Augstein, P; Bandala-Sanchez, E; Campbell, P; Harrison, LC; Hawthorne, WJ; Heinke, P; Kay, TW; Loudovaris, T; Naselli, G; Rogers, K; Thomas, HE | 1 |
Benatti, FB; Harder-Lauridsen, NM; Krogh-Madsen, R; Lyngbæk, MP; Møller, K; Nielsen, ST; Pedersen, BK; Wedell-Neergaard, AS | 1 |
Iwasaki, M; Kurose, T; Kuwata, H; Maeda, H; Minami, K; Murotani, K; Nakada, K; Nosaka, C; Seino, S; Seino, Y; Shimizu, S; Yabe, D | 1 |
Gluud, L; Holst, JJ; Junker, AE; Knop, FK; Vilsbøll, T | 1 |
Chae, KS; Choi, OK; Chung, SS; Ham, DS; Jung, HS; Kim, JW; Kim, MJ; Lee, H; Park, KS; Yoon, KH | 1 |
Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X | 1 |
Deacon, CF; Eelderink, C; Holst, JJ; Koehorst, M; Noort, MWJ; Oudhuis, L; Poutanen, K; Priebe, MG; Rehfeld, JF; Sozer, N; Vonk, RJ | 1 |
Åsberg, A; Egeland, EJ; Feldt-Rasmussen, B; Halden, TA; Hartmann, A; Holst, JJ; Hornum, M; Jenssen, T; Khiabani, HZ; Knop, FK; Midtvedt, K | 1 |
Beglinger, C; Cajacob, L; Drewe, J; Herzog, R; Meyer-Gerspach, AC; Riva, D; Wölnerhanssen, BK | 1 |
Dincer, F; Farr, OM; Gavrieli, A; Hamnvik, OP; Mantzoros, CS; Sahin-Efe, A; Vamvini, MT | 1 |
Arslanian, S; Bacha, F; Hannon, T; Hughan, KS; Kim, JY; Lee, S; Michaliszyn, SF; Nasr, A; Tfayli, H | 1 |
Cuchel, M; De Leon, DD; Gudipaty, L; Hadjiliadis, D; Kelly, A; Kubrak, C; Malik, S; Nyirjesy, SC; Peleckis, AJ; Rickels, MR; Rosenfeld, NK; Rubenstein, RC; Sheikh, S; Stefanovski, D | 1 |
Jütte, H; Meier, J; Montanya, E; Nauck, M; Schmidt, W; Tannapfel, A; Ueberberg, S; Uhl, W | 1 |
Jiang, G; Liang, G; Song, X; Wang, F; Xu, H; Zhang, L; Zhou, L | 1 |
Gilbert, JD; Goldenberg, RM; Perkins, BA; Verma, S; Zinman, B | 1 |
Bagger, JI | 1 |
Coppieters, K; Hasselby, JP; Kirk, RK; Knudsen, LB; Mortensen, PG; Pedersen, L; Pyke, C; von Herrath, MG | 1 |
Beaudry, JL; Campbell, JE; Cao, X; Drucker, DJ; Flock, GB; Panaro, BL | 1 |
Habener, JF; Stanojevic, V | 1 |
Bozkurt, S; Cira, DK; Ozdem, S; Sari, R; Yilmaz, N | 1 |
Bloom, S; Cegla, J; Creaser, CS; Howard, JW; Jones, B; Kay, RG; Tan, T | 1 |
Junker, AE | 1 |
Anděl, M; Gojda, J; Plíhalová, A; Polák, J; Potočková, J; Straková, R; Tůma, P | 1 |
Holst, JJ; Knop, FK; Pedersen, J; Wewer Albrechtsen, NJ | 1 |
Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Watson, LE; Wu, T | 1 |
Marks, V | 1 |
Seufert, J | 1 |
Bunzel, M; Cheewatrakoolpong, B; Chobanian, HR; Colletti, SL; Di Salvo, J; Feng, Y; Forrest, G; Howard, AD; Kirkland, ME; Kosinski, DT; Li, X; Mane, J; Miller, C; Miller, MW; Ogawa, AM; Pachanski, MJ; Plummer, CW; Souza, S; Szeto, D; Tatosian, DA; Thomas-Fowlkes, BS; Trujillo, ME; Weinglass, AB; Xue, J | 1 |
Ahlqvist, E; Almgren, P; Asplund, O; Groop, L; Hakaste, L; Holst, JJ; Krus, U; Laurila, E; Lindqvist, A; Melander, O; Nilsson, PM; Orho-Melander, M; Ottosson-Laakso, E; Prasad, RB; Sonestedt, E; Tuomi, T; Wierup, N | 1 |
Chamarthi, B; Chen, L; Florez, JC; Goldfine, A; Hudson, M; Kaur, V; Littleton, KR; Manning, AK; Merino, J; Srinivasan, S; Thomas, MK | 1 |
Bloom, SR; Scott, RV | 1 |
Trautmann, ME; Vora, J | 1 |
Engelbrechtsen, L; Færch, K; Gjesing, AP; Grarup, N; Hansen, T; Holst, JJ; Jonsson, A; Jørgensen, ME; Jørgensen, T; Kanters, JK; Mahendran, Y; Pedersen, O; Torekov, S; Vestergaard, H; Weeke, PE; Witte, DR | 1 |
Berger, C; Friedrich, A; Koepsell, H; Metzger, M; Mühlemann, M; Otto, C; Walles, H; Zdzieblo, D | 1 |
Heinla, I; Jagomäe, T; Koppel, T; Pallase, M; Plaas, M; Seppa, K; Terasmaa, A; Toots, M; Vasar, E | 1 |
D'Aiuto, F; Gennai, S; Graziani, F; Masi, S; Petrini, M; Santini, E; Seghieri, M; Solini, A; Suvan, J | 1 |
Chikh, K; Marchand, L; Thivolet, C | 1 |
D'Alessio, DA; Gastaldelli, A; Salehi, M | 1 |
Alfieri, S; Capece, U; Carfì, A; Cefalo, CMA; Cinti, F; Ferraro, PM; Giaccari, A; Holst, JJ; Impronta, F; Mari, A; Mezza, T; Moffa, S; Pontecorvi, A; Quero, G; Sorice, GP | 1 |
Bhansali, A; Bhansali, S; Bhat, K; Dutta, P; Kochhar, R; Kurpad, AV; Mudaliar, S; Mukherjee, KK; Sachdeva, N; Shekhawat, VS; Sinha, SK; Vaiphei, K | 1 |
Abrahamsson, N; Almby, KE; Eriksson, JW; Hammar, U; Karlsson, FA; Lundqvist, MH; Panagiotou, A; Sundbom, M; Thombare, K; Wiklund, U | 1 |
De Leon, DD; Hadjiliadis, D; Kelly, A; Kilberg, MJ; Kubrak, C; Rickels, MR; Rubenstein, RC; Sheikh, S; Stefanovski, D | 1 |
Brandi, L; Bressendorff, I; Feldt-Rasmussen, B; Hansen, HP; Hartmann, B; Holst, JJ; Hornum, M; Idorn, T; Jørgensen, MB; Knop, FK; Rydahl, C; van Hall, G; Wewer Albrechtsen, NJ | 1 |
Brooks, A; Guyton, J; Jeon, M | 1 |
Abbara, A; Bech, P; Comninos, AN; Coumbe, B; Crustna, Y; Dhillo, WS; Eng, PC; Izzi-Engbeaya, C; Jones, S; Machenahalli, PC; Mills, E; Minnion, J; Modi, M; Pacuszka, E; Panayi, C; Papadopoulou, D; Phylactou, M; Plumptre, I; Ratnasabapathy, R; Starikova, J; Sykes, M; Tan, T; Tharakan, G; Veldhuis, J; Wing, VC; Yang, L | 1 |
Bojsen-Møller, KN; Dirksen, C; Fenger, M; Holst, JJ; Kristiansen, VB; Madsbad, S; Martinussen, C; Svane, MS; van Hall, G; Veedfald, S; Wewer Albrechtsen, NJ | 1 |
Ahrén, B; Pacini, G | 1 |
Ali Mondal, S; Anne M, B; Basu, M; Chakrabarti, P; Das, K; Ghosh, I; Ghosh, S; Mukhopadhyay, P; Nargis, T; Pandit, K | 1 |
Brown, JL; Campbell, JE; Capozzi, ME; Chazotte, BM; Clifford, A; D'Alessio, DA; El, K; Encisco, SE; Gray, SM; Jin, E; Knuth, ER; Merrins, MJ; Nunez, DJ; Sloop, KW; Svendsen, B | 1 |
Broughton, KS; LeMieux, MJ; Rao, M; Zumbro, EL | 1 |
Hoshino, R; Kamiyama, T; Kondo, S; Kosakamoto, H; Matsuoka, R; Nakamura, A; Niwa, R; Obata, F; Tanimoto, H; Yoshinari, Y | 1 |
Del Prato, S; Gallwitz, B; Holst, JJ; Meier, JJ | 1 |
Choi, YK; Jeon, JH; Kwon, OK; Park, JY; Park, KB | 1 |
Mandarim-de-Lacerda, CA; Spezani, R | 1 |
Bando, S; Fujimoto, K; Ichikawa, R; Miyatsuka, T; Motomiya, T; Shichiri, M; Taguchi, M; Taguchi, T; Takano, K | 1 |
Chepurny, OG; Collier, JJ; Cooney, RN; Holz, GG; Leech, CA; Meng, Q; Molnar, ME; Pruekprasert, N | 1 |
Barbot, M; Basso, D; Ceccato, F; Giordano, C; Guarnotta, V; Mondin, A; Regazzo, D; Scaroni, C | 1 |
D'Alessio, DA; De Leon, DD; Doliba, A; Eiel, JN; Flatt, AJ; Gallagher, K; Gallop, R; Hadjiliadis, D; Kelly, A; Nyirjesy, SC; Peleckis, AJ; Rickels, MR; Rubenstein, RC; Sheikh, S; Stefanovski, D; Tami, A | 1 |
Brown, T; Carlson, OD; Clark, JM; Egan, JM; Langan, S; Lee, CJ; Schweitzer, M | 1 |
Forman, JL; Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; Vilsbøll, T | 1 |
Biancolin, AD; Brubaker, PL; Jeong, H; Martchenko, A; Srikrishnaraj, A | 1 |
Aguilar-Ballester, M; González-Navarro, H; Hurtado-Genovés, G; Jiménez-Martí, E; Martínez-Hervás, S | 1 |
Fridh, MK; Gerbek, T; Hartmann, B; Holst, JJ; Mathiesen, S; Müller, K; Nissen, AA; Soerum, ME; Sørensen, K; Vadmand, AC | 1 |
Artoni, RF; Caproni, P; Cleva, R; Estabile, PC; Kuga, R; Milléo, FQ; Mota, FC; Moura, EGH; Santo, MA | 1 |
Javeed, N; Sen, S | 1 |
Rehfeld, JF | 1 |
Gallwitz, B | 1 |
Csanalosi, M; Kabisch, S; Kemper, M; Keyhani-Nejad, F; Markova, M; Meyer, NMT; Pfeiffer, AFH; Pivovarova-Ramich, O; Rohn, S; Schäfer, SM; Schuppelius, B; Zhang, J | 1 |
Babu, S; Gowshika, K; Kumar, NP; Lakshan Raj, S; Mittal, R; Pandiarajan, AN; Putlibai, S; Rajamanickam, A; Ramanan, PV; Sasidaran, R; Selvaraj, N; Venkataraman, A | 1 |
Barber, TM; Hanson, P; Kyrou, I; Pelling, M; Randeva, H; Statham, L | 1 |
Gasbjerg, LS; Holst, JJ; Knop, FK; Meier, JJ; Rosenkilde, MM | 1 |
Andrews, RC; Bowman, P; Flanagan, SE; Hammersley, S; Hartmann, B; Hattersley, AT; Holst, JJ; Knight, BA; Leveridge, M; McDonald, TJ; Patel, KA; Shepherd, MH; Shields, BM; Spaull, SR | 1 |
D'Alessio, DA; Marks, V | 1 |
32 review(s) available for glucagon and incretins
Article | Year |
---|---|
Dipeptidyl peptidase IV inhibitors and diabetes therapy.
Topics: Animals; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon; Glucose; Homeostasis; Humans; Incretins; Insulin; Insulin Resistance; Models, Biological | 2008 |
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
An overview of incretin hormones.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Humans; Incretins; Insulin Resistance; Insulin-Secreting Cells | 2008 |
The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
Topics: Adipose Tissue; Body Weight; Diabetes Mellitus, Type 2; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Insulin; Insulin Secretion; Overweight; Receptors, Glucagon | 2008 |
Exenatide: a review from pharmacology to clinical practice.
Topics: Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Exenatide; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Peptides; Randomized Controlled Trials as Topic; Venoms; Weight Loss | 2009 |
Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Middle Aged; Nurse Practitioners; Patient Selection; Primary Health Care | 2008 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
New physiological effects of the incretin hormones GLP-1 and GIP.
Topics: Adult; Appetite; Eating; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Islet Amyloid Polypeptide; Male; Postprandial Period | 2011 |
Is the GLP-1 system a viable therapeutic target for weight reduction?
Topics: Animals; Body Weight; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Weight Loss | 2011 |
Type 2 diabetes across generations: from pathophysiology to prevention and management.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diabetic Retinopathy; Epigenesis, Genetic; Female; Fetal Development; Genetic Predisposition to Disease; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Incretins; Insulin Resistance; Insulin-Secreting Cells; Life Style; Liver; Muscle, Skeletal; Myocardium; Obesity; Prediabetic State; Pregnancy | 2011 |
Incretin hormones and the expanding families of glucagon-like sequences and their receptors.
Topics: Animals; Base Sequence; Chickens; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptides; Humans; Incretins; Mammals; Phylogeny; Protein Precursors; Receptors, Glucagon; Xenopus | 2011 |
Regulation of glucagon secretion by incretins.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Rats; Receptors, Glucagon | 2011 |
Insulin sensitivity and secretion modifications after bariatric surgery.
Topics: Animals; Bariatric Surgery; Body Mass Index; Diabetes Mellitus, Type 2; Gastric Mucosa; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Incretins; Insulin Resistance; Insulin-Secreting Cells; Intestinal Mucosa; Obesity, Morbid | 2012 |
[Effects of GLP-1 (glucagon-like peptide 1) on liver].
Topics: Animals; Glucagon; Glucagon-Like Peptide 1; Hepatocytes; Humans; Hypoglycemic Agents; Incretins; Insulin; Lipid Metabolism; Liver Diseases; Non-alcoholic Fatty Liver Disease; Oxidative Stress | 2013 |
[New therapies for type 2 diabetes mellitus].
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Diacylglycerol O-Acyltransferase; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Drugs, Investigational; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucokinase; Gluconeogenesis; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Insulin, Long-Acting; Molecular Targeted Therapy; Obesity; Phosphofructokinase-2; Sodium-Glucose Transport Proteins; Weight Loss | 2015 |
Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism.
Topics: Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Microcirculation; Muscle, Skeletal | 2014 |
Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus; Drug Therapy, Combination; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Incretins; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Physiological and pathophysiological aspects of incretin hormones and glucagon.
Topics: Animals; Appetite; Diabetes Mellitus, Type 2; Enteroendocrine Cells; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Oxyntomodulin; Peptide Fragments | 2017 |
The role of incretin hormones and glucagon in patients with liver disease.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Intolerance; Humans; Incretins; Insulin; Liver; Mice; Non-alcoholic Fatty Liver Disease | 2017 |
The Gut: A Key to the Pathogenesis of Type 2 Diabetes?
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Gastrointestinal Tract; Glucagon; Humans; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Intestines; Postprandial Period | 2017 |
Genetic determinants of circulating GIP and GLP-1 concentrations.
Topics: ABO Blood-Group System; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enteroendocrine Cells; Female; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Gastrointestinal Tract; Genetic Variation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-2 Receptor; Glucose; Glucose Tolerance Test; Homeodomain Proteins; Humans; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Prospective Studies; Receptors, Gastrointestinal Hormone; RNA, Messenger; Sodium-Glucose Transporter 1 | 2017 |
Problem or solution: The strange story of glucagon.
Topics: Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Humans; Hyperglycemia; Incretins; Insulin; Obesity; Receptors, Glucagon | 2018 |
Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Peptides; Postprandial Period; Treatment Outcome | 2018 |
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Exenatide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Treatment Outcome; Weight Loss | 2019 |
Glucose effectiveness: Lessons from studies on insulin-independent glucose clearance in mice.
Topics: Administration, Intravenous; Adult; Aged; Animals; Biological Transport; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Male; Mice; Middle Aged | 2021 |
The incretin/glucagon system as a target for pharmacotherapy of obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Obesity | 2022 |
The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Obesity | 2022 |
Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Incretins; Peptides; Proglucagon | 2022 |
Four sidenotes about glucagon peptides.
Topics: Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Incretins; Peptides | 2023 |
[Gastrointestinal hormones: their increasing pharmacotherapeutic relevance in metabolic diseases].
Topics: Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins | 2023 |
The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins | 2023 |
38 trial(s) available for glucagon and incretins
Article | Year |
---|---|
The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Critical Illness; Cross-Over Studies; Double-Blind Method; Enteral Nutrition; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemia; Incretins; Infusions, Intravenous; Insulin; Male; Middle Aged | 2009 |
Acute effects of casein on postprandial lipemia and incretin responses in type 2 diabetic subjects.
Topics: Aged; Biomarkers; Blood Glucose; Caseins; Chylomicrons; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Diterpenes; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Postprandial Period; Retinyl Esters; Time Factors; Triglycerides; Vitamin A | 2010 |
Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
Topics: Administration, Oral; Adult; Appetite; Blood Glucose; Caprylates; Cross-Over Studies; Double-Blind Method; Drug Carriers; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Homeostasis; Human Growth Hormone; Humans; Incretins; Insulin; Intestinal Absorption; Male; Peptide Fragments; Postprandial Period; Reference Values; Young Adult | 2009 |
Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis.
Topics: Adult; Appetite; Blood Glucose; C-Peptide; Cross-Over Studies; Double-Blind Method; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Hunger; Immunoassay; Incretins; Insulin; Male; Peptide YY; Satiety Response | 2010 |
Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation.
Topics: Adult; Blood Glucose; Cystic Fibrosis; Dietary Carbohydrates; Dietary Fats; Double-Blind Method; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Insulin; Lipase; Male; Pancreas; Young Adult | 2011 |
Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
Topics: Adult; Blood Glucose; C-Peptide; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Intolerance; Glucose Tolerance Test; Humans; Incretins; Infusions, Intravenous; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Kinetics; Male; Severity of Illness Index; Young Adult | 2012 |
The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Clamp Technique; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Peptide Fragments; Receptors, Glucagon | 2012 |
Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?
Topics: Adolescent; Adult; Anthropometry; Arginine; Blood Glucose; Dose-Response Relationship, Drug; Double-Blind Method; Glucagon; Glucocorticoids; Glucose Clamp Technique; Heart Rate; Humans; Hyperglycemia; Incretins; Islets of Langerhans; Male; Pancreatic Diseases; Pancreatic Function Tests; Prednisolone; Stimulation, Chemical; Sympathetic Nervous System; Vagus Nerve; Young Adult | 2013 |
Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men.
Topics: Adult; Benzamides; Blood Glucose; Gastric Inhibitory Polypeptide; Gastrointestinal Agents; Gastrointestinal Tract; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Morpholines; Postprandial Period; Serotonin 5-HT4 Receptor Agonists; Up-Regulation | 2013 |
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Peptides | 2013 |
Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Duodenum; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glutamine; Healthy Volunteers; Humans; Incretins; Insulin; Insulin Secretion; Male | 2013 |
Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects.
Topics: Antioxidants; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Method; Fasting; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Male; Middle Aged; Obesity; Postprandial Period; Resveratrol; Stilbenes; Time Factors; Treatment Outcome | 2013 |
Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial.
Topics: Adolescent; Blood Glucose; Child; Cross-Over Studies; Cystic Fibrosis; Enzyme Replacement Therapy; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Male; Pancrelipase; Postprandial Period | 2014 |
Impaired incretin secretion and pancreatic dysfunction with older age and diabetes.
Topics: Adiponectin; Adipose Tissue; Adult; Aged; Aging; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Down-Regulation; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Pancreas; Postprandial Period; Up-Regulation | 2014 |
Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; China; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Male; Middle Aged; Postprandial Period; Predictive Value of Tests; Time Factors; Young Adult | 2015 |
Decreased insulin secretion and incretin concentrations and increased glucagon concentrations after a high-fat meal when compared with a high-fruit and -fiber meal.
Topics: Adult; Diet, High-Fat; Dietary Fats; Dietary Fiber; Down-Regulation; Female; Fruit; Glucagon; Humans; Incretins; Insulin; Insulin Secretion; Male; Meals; Middle Aged; Up-Regulation; Young Adult | 2015 |
Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Food; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Sitagliptin Phosphate | 2014 |
Accelerated intestinal glucose absorption in morbidly obese humans: relationship to glucose transporters, incretin hormones, and glycemia.
Topics: 3-O-Methylglucose; Adult; Blood Glucose; Female; Gastric Inhibitory Polypeptide; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Transport Proteins, Facilitative; Humans; Incretins; Insulin; Intestinal Absorption; Male; Middle Aged; Obesity, Morbid; Time Factors | 2015 |
Incretin effect after oral amino acid ingestion in humans.
Topics: Administration, Oral; Adult; Amino Acids; Blood Glucose; C-Peptide; Eating; Electrolytes; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Incretins; Insulin; Insulin Secretion; Male; Solutions; Young Adult | 2015 |
Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients.
Topics: Adult; Aged; Blood Glucose; Eating; Female; Food; Glucagon; Glucose Tolerance Test; Humans; Hyperglycemia; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Time Factors; Young Adult | 2015 |
Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.
Topics: Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Growth Hormone; Humans; Hypoglycemia; Incretins; Male; Middle Aged; Sitagliptin Phosphate; Young Adult | 2015 |
Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Male; Middle Aged; Postprandial Period | 2015 |
Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Limosilactobacillus reuteri; Male; Middle Aged; Obesity; Oxidative Stress; Pilot Projects; Probiotics; Prospective Studies; Protein Precursors | 2015 |
Prior exercise does not alter the incretin response to a subsequent meal in obese women.
Topics: Adult; Blood Glucose; Eating; Exercise; Female; Glucagon; Humans; Incretins; Obesity | 2015 |
The structure of wheat bread influences the postprandial metabolic response in healthy men.
Topics: Bile Acids and Salts; Blood Glucose; Body Mass Index; Bread; Breath Tests; Carbon Dioxide; Cross-Over Studies; Gastric Inhibitory Polypeptide; Glucagon; Humans; Incretins; Insulin; Insulin Resistance; Male; Portion Size; Postprandial Period; Triticum; Young Adult | 2015 |
Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Topics: Academic Dissertations as Topic; Adult; Blood Glucose; Cross-Over Studies; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Islets of Langerhans; Male; Postprandial Period | 2015 |
Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
Topics: Adult; Aged; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Incretins; Insulin; Japan; Male; Meals; Middle Aged; Postprandial Period | 2016 |
Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
Topics: Adult; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Incretins; Insulin; Male; Middle Aged; Non-alcoholic Fatty Liver Disease | 2016 |
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins | 2016 |
Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men.
Topics: Appetite; Bile Acids and Salts; Blood Glucose; Body Mass Index; Bread; Cross-Over Studies; Dietary Fiber; Flour; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Male; Particle Size; Postprandial Period; Triticum; Young Adult | 2017 |
GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Incretins; Infusions, Intravenous; Insulin; Insulin Secretion; Kidney Transplantation; Male; Middle Aged; Proinsulin | 2016 |
Mechanisms Regulating Insulin Response to Intragastric Glucose in Lean and Non-Diabetic Obese Subjects: A Randomized, Double-Blind, Parallel-Group Trial.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; C-Peptide; Case-Control Studies; Diabetes Mellitus; Double-Blind Method; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Incretins; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Young Adult | 2016 |
Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
Topics: Adult; Blood Glucose; Catecholamines; Cross-Over Studies; Exenatide; Female; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Heart Rate; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Incretins; Male; Middle Aged; Parasympathetic Nervous System; Postoperative Period; Sympathetic Nervous System | 2019 |
Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease.
Topics: Adult; Denmark; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2020 |
Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men.
Topics: Adult; Biomarkers; Cross-Over Studies; Follow-Up Studies; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin Secretion; Male; Prognosis; Reproduction; Single-Blind Method; Young Adult | 2020 |
The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
Topics: Blood Glucose; C-Peptide; Canagliflozin; Cross-Over Studies; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Middle Aged; Pancreatic Polypeptide; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of GLP-1 and GIP on Islet Function in Glucose-Intolerant, Pancreatic-Insufficient Cystic Fibrosis.
Topics: Adult; Arginine; Blood Glucose; Cystic Fibrosis; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Incretins; Insulin; Proinsulin | 2022 |
The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.
Topics: Biphenyl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Incretins; Insulin; Receptors, Glucagon | 2022 |
94 other study(ies) available for glucagon and incretins
Article | Year |
---|---|
The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Male; Middle Aged; Pancreatitis, Chronic | 2007 |
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
Topics: Adipokines; Adipose Tissue; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Corticosterone; Dietary Fats; Eating; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Incretins; Insulin; Insulin Resistance; Lipids; Liver; Male; Mice; Motor Activity; Muscle, Skeletal; Obesity; Pancreas; Receptors, Gastrointestinal Hormone | 2007 |
Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Eating; Female; Food; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Incretins; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Obesity, Morbid; Postoperative Complications | 2007 |
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Intolerance; Glucose Tolerance Test; Humans; Incretins; Male; Middle Aged; Triglycerides | 2008 |
Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Reducing; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Male; Middle Aged; Obesity; Weight Loss | 2008 |
Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
Topics: Adult; Blood Glucose; Body Water; Diet; Dietary Fats; Dietary Proteins; Dipeptidyl Peptidase 4; Fatty Acids, Nonesterified; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Islets of Langerhans; Male; Pancreatic Hormones; Triglycerides | 2008 |
Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men.
Topics: Adult; Blood Glucose; C-Peptide; Fatty Acids, Nonesterified; Gastric Inhibitory Polypeptide; Glucagon; Humans; Incretins; Insulin; Islets of Langerhans; Male; Postprandial Period; Time Factors | 2009 |
Incretins in the ICU: is insulin on its way out?
Topics: Female; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Incretins; Insulin; Intensive Care Units; Male; Outcome Assessment, Health Care | 2009 |
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report.
Topics: Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Enteral Nutrition; Fatty Acids, Nonesterified; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Male; Middle Aged; Obesity, Morbid; Peptide YY; Postoperative Period; Postprandial Period | 2010 |
The time has come for incretins, a long time coming.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon; Humans; Incretins; Mice; Models, Biological; Pancreas | 2010 |
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Peptides; Phenotype; Receptors, Glucagon; Venoms | 2009 |
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.
Topics: Adult; Area Under Curve; Blood Glucose; Body Weight; C-Peptide; Diet; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Resistance; Male; Motor Activity; Prednisolone | 2010 |
Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
Topics: Aged; Analysis of Variance; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Male; Middle Aged; Postprandial Period | 2010 |
Effects of physiological hyperglycemia on duodenal motility and flow events, glucose absorption, and incretin secretion in healthy humans.
Topics: Adult; Analysis of Variance; Area Under Curve; Blood Glucose; Duodenum; Electric Impedance; Female; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hyperglycemia; Incretins; Insulin; Male; Manometry; Single-Blind Method | 2010 |
Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Leptin; Middle Aged; Obesity, Morbid; Postoperative Period; Stomach; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Peptides | 2011 |
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.
Topics: Animals; Cholecystokinin; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Incretins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxygen Consumption; Pancreas; Phenotype; Rats; Receptors, Glucagon | 2011 |
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Obesity | 2012 |
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Increased action of pulsatile compared to non-pulsatile insulin delivery during a meal-like glucose exposure simulated by computerized infusion in healthy humans.
Topics: Adult; Biomarkers; Blood Glucose; C-Peptide; Computer Simulation; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Female; Glucagon; Human Growth Hormone; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Infusion Systems; Insulin Secretion; Male; Pancreatic Hormones; Pituitary Hormones; Postprandial Period; Pulsatile Flow; Research Design; Time Factors | 2012 |
MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucose; Glucose Intolerance; Homeostasis; Hyperglycemia; Hyperinsulinism; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Obese; Phenylalanine; Triazoles | 2012 |
Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele.
Topics: Alleles; Blood Glucose; Female; Gastric Inhibitory Polypeptide; Genotype; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Incretins; Insulin; Male; Middle Aged; Transcription Factor 7-Like 2 Protein; White People | 2013 |
Activation of enteroendocrine membrane progesterone receptors promotes incretin secretion and improves glucose tolerance in mice.
Topics: Animals; Enteroendocrine Cells; Extracellular Signal-Regulated MAP Kinases; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Homeostasis; Incretins; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Promegestone; Receptors, Progesterone | 2013 |
Impact of incretin on early-phase insulin secretion and glucose excursion.
Topics: Adult; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged | 2013 |
Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease.
Topics: Adult; Analysis of Variance; Area Under Curve; Biomarkers; Blood Glucose; Case-Control Studies; Fasting; Female; Gastric Inhibitory Polypeptide; Gastrointestinal Tract; Glucagon; Glucagon-Like Peptide 1; Glucose Metabolism Disorders; Glucose Tolerance Test; Humans; Incretins; Insulin; Kidney Failure, Chronic; Linear Models; Male; Middle Aged; Time Factors | 2013 |
The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes.
Topics: Adult; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Republic of Korea | 2014 |
Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT.
Topics: Adult; Aged; Alanine Transaminase; Area Under Curve; Biomarkers; Diabetes Mellitus, Type 2; Eating; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Incretins; Lipid Metabolism; Male; Middle Aged; Triglycerides | 2013 |
Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease.
Topics: Adult; Blood Glucose; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Kidney Failure, Chronic; Male; Middle Aged; Pancreatic Hormones; Postprandial Period | 2014 |
Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia.
Topics: Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Diabetes Mellitus, Type 1; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Glycerol Kinase; Humans; Hypoadrenocorticism, Familial; Incretins; Male; Middle Aged | 2014 |
Intracerebroventricular administration of novel glucagon-like peptide suppresses food intake in chicks.
Topics: Animals; Appetite Depressants; Blood Glucose; Brain; Chickens; Corticosterone; Eating; Glucagon; Glucagon-Like Peptide 1; Incretins; Male; Oxyntomodulin; Receptors, Corticotropin-Releasing Hormone | 2014 |
Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Prediabetic State | 2014 |
GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.
Topics: Adolescent; Adult; Blood Flow Velocity; Blood Volume; Coronary Vessels; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Microvessels; Muscle, Skeletal; Regional Blood Flow | 2014 |
Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.
Topics: Administration, Intravenous; Administration, Oral; Adult; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucokinase; Glucose; Hepatocyte Nuclear Factor 1-alpha; Humans; Incretins; Insulin Resistance; Male; Middle Aged | 2014 |
Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes.
Topics: Animals; Blood Glucose; Body Mass Index; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Incretins; Insulin; Male | 2014 |
Generation of high-yield insulin producing cells from human bone marrow mesenchymal stem cells.
Topics: Activins; Basic Helix-Loop-Helix Transcription Factors; Biomarkers; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Culture Media; Exenatide; Gene Expression; Glucagon; Hepatocyte Growth Factor; Hepatocyte Nuclear Factor 3-beta; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Incretins; Insulin; Insulin-Secreting Cells; Mesenchymal Stem Cells; Nerve Tissue Proteins; Nuclear Proteins; Peptides; Somatostatin; SOXF Transcription Factors; Taurine; Trans-Activators; Transcription Factors; Venoms; Zebrafish Proteins | 2014 |
Diabetes. Attenuated incretin effect after glucose loading in monogenic HNF1A diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Humans; Incretins; Male | 2014 |
Meal feeding improves oral glucose tolerance in male rats and causes adaptations in postprandial islet hormone secretion that are independent of plasma incretins or glycemia.
Topics: Allostasis; Animals; Behavior, Animal; Feeding Behavior; Gastric Inhibitory Polypeptide; Glucagon; Glucose Intolerance; Hyperglycemia; Ileum; Incretins; Insulin; Insulin Secretion; Intestinal Mucosa; Islets of Langerhans; Jejunum; Male; Meals; Neurosecretory Systems; Organ Specificity; Postprandial Period; Proglucagon; Rats, Long-Evans | 2014 |
[The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Topics: Animals; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Eating; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Homeostasis; Humans; Hyperglycemia; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Malabsorption Syndromes; Mice; Mice, Knockout; Models, Biological; Obesity; Receptors, Glucagon | 2014 |
Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
Topics: Diabetes Mellitus, Type 2; Dynamin I; Gastric Inhibitory Polypeptide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide-1 Receptor; HEK293 Cells; Humans; Incretins; Islets of Langerhans; Ligands; Protein Transport; Receptors, G-Protein-Coupled; Receptors, Glucagon; Signal Transduction | 2015 |
Incretin secretion in obese Korean children and adolescents with newly diagnosed type 2 diabetes.
Topics: Adolescent; Analysis of Variance; Asian People; Blood Glucose; Body Mass Index; C-Peptide; Case-Control Studies; Child; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Resistance; Male; Obesity; Republic of Korea | 2016 |
Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Gastrointestinal Tract; Glucagon; Glucose; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Prediabetic State; Psoriasis; Reproducibility of Results; Severity of Illness Index | 2015 |
Degradation and Stabilization of Peptide Hormones in Human Blood Specimens.
Topics: Amino Acid Sequence; Dipeptidyl Peptidase 4; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Molecular Sequence Data; Oxyntomodulin; Peptide Fragments; Peptide Hormones; Protein Stability; Proteolysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Blood Glucose; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Proteins; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Healthy Volunteers; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Meals; Middle Aged; Postprandial Period | 2016 |
Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Immunohistochemistry; Incretins; Insulin-Secreting Cells; Male; Middle Aged; Pancreatic Ducts; Proinsulin; Young Adult | 2015 |
The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers.
Topics: Adolescent; Adult; Bed Rest; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucose; Glucose Tolerance Test; Healthy Volunteers; Humans; Incretins; Insulin; Insulin Resistance; Male; Young Adult | 2016 |
Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells.
Topics: Animals; Autophagy; Diabetes Mellitus, Experimental; Glucagon; Glucagon-Secreting Cells; Glucose Intolerance; Incretins; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice | 2015 |
Differential Effects of Oral and Intravenous Lipid Administration on Key Molecules Related to Energy Homeostasis.
Topics: Adiponectin; Administration, Oral; Adult; alpha-2-HS-Glycoprotein; Blood Glucose; C-Peptide; Cytokines; Energy Metabolism; Fatty Acids, Nonesterified; Female; Fibroblast Growth Factors; Fibronectins; Ghrelin; Glucagon; GPI-Linked Proteins; Homeostasis; Humans; Incretins; Infusions, Intravenous; Insulin; Lectins; Lipids; Male; Middle Aged; Peptide YY; Young Adult | 2016 |
The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth.
Topics: Adiposity; Adolescent; Biomarkers; Blood Glucose; Body Composition; Body Mass Index; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Incretins; Insulin; Insulin Secretion; Male; Pediatric Obesity; Risk Factors | 2016 |
Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance.
Topics: Adolescent; Adult; C-Peptide; Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Pancreas; Proinsulin; Young Adult | 2017 |
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Topics: Acinar Cells; Adamantane; Adenocarcinoma; Adult; Aged; Carcinoma in Situ; Case-Control Studies; Cystadenoma; Diabetes Mellitus, Type 2; Digestive System Surgical Procedures; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Secreting Cells; Humans; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Neuroendocrine Tumors; Nitriles; Organ Size; Pancreas; Pancreas, Exocrine; Pancreatic Neoplasms; Pancreatitis, Chronic; Peptides; Pyrrolidines; Sitagliptin Phosphate; Tissue Donors; Venoms; Vildagliptin | 2016 |
Acute Reduction of Incretin Effect and Glucose Intolerance in Rats by Single Intragastric Administration of 3-deoxyglucosone.
Topics: Animals; Cyclic AMP; Deoxyglucose; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Incretins; Insulin; Male; Mice; Prediabetic State; Rats | 2017 |
Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibody Specificity; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Image Processing, Computer-Assisted; Immunohistochemistry; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Pancreas; Tissue Banks; Young Adult | 2017 |
β-Cell Inactivation of
Topics: Adipokines; Animals; Apoptosis; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Gene Expression Profiling; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Mice, Knockout; Oxadiazoles; Pyrimidines; Receptors, G-Protein-Coupled | 2017 |
Pancreas and Not Gut Mediates the GLP-1-Induced Glucoincretin Effect.
Topics: Animals; Glucagon; Glucagon-Like Peptide 1; Incretins; Insulin; Mice; Pancreas; Peptide Fragments | 2017 |
GLP-1 and GIP Levels in Patients With Hyperthyroidism: The Effect of Antithyroid Treatment.
Topics: Adult; Antithyroid Agents; Blood Glucose; Case-Control Studies; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hyperthyroidism; Incretins; Insulin; Male; Middle Aged | 2017 |
Development of a UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon and dosed GLP-1 from human plasma.
Topics: Chromatography, High Pressure Liquid; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Limit of Detection; Tandem Mass Spectrometry | 2017 |
Increased Incretin But Not Insulin Response after Oral versus Intravenous Branched Chain Amino Acids.
Topics: Administration, Intravenous; Administration, Oral; Adult; Amino Acids, Branched-Chain; Blood Glucose; C-Peptide; Dose-Response Relationship, Drug; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Isoleucine; Leucine; Male; Valine; Young Adult | 2017 |
Comparative effects of intraduodenal fat and glucose on the gut-incretin axis in healthy males.
Topics: Adult; Blood Glucose; Duodenum; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucose; Healthy Volunteers; Humans; Incretins; Insulin; Insulin Secretion; Intestine, Small; Male; Postprandial Period | 2017 |
Rebirth of the Incretin Concept: Its conception and early development.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hyperglycemia; Incretins; Insulin; Peptide Fragments | 2018 |
Incretins and Their Endocrine and Metabolic Functions.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Tract; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells | 2017 |
GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
Topics: Animals; Cell Line; CHO Cells; Cricetulus; Glucagon; Glucose; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Rats; Receptors, G-Protein-Coupled | 2017 |
Topics: Adult; Aged; Alleles; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotyping Techniques; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Metformin; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Risk Factors; Sulfonylurea Compounds; Transcription Factor 7-Like 2 Protein | 2018 |
Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses.
Topics: Aged; Cohort Studies; Denmark; ERG1 Potassium Channel; Fasting; Female; Gain of Function Mutation; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Incretins; Long QT Syndrome; Male; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors | 2018 |
Altered pancreatic islet morphology and function in SGLT1 knockout mice on a glucose-deficient, fat-enriched diet.
Topics: Animals; Blood Glucose; Diet, High-Fat; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Mice; Mice, Knockout; Pancreas; Sodium-Glucose Transporter 1 | 2018 |
Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome.
Topics: Animals; Blood Glucose; Calmodulin-Binding Proteins; Disease Models, Animal; Endoplasmic Reticulum Stress; Gene Knockout Techniques; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Intolerance; Glucose Tolerance Test; Humans; Incretins; Injections, Subcutaneous; Insulin; Islets of Langerhans; Liraglutide; Male; Membrane Proteins; Rats; Rats, Transgenic; Treatment Outcome; Wolfram Syndrome | 2018 |
Periodontitis affects glucoregulatory hormones in severely obese individuals.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Gastric Inhibitory Polypeptide; Glucagon; Humans; Incretins; Insulin; Male; Middle Aged; Obesity, Morbid; Periodontitis | 2019 |
Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide.
Topics: Adult; Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Young Adult | 2019 |
Role of vagal activation in postprandial glucose metabolism after gastric bypass in individuals with and without hypoglycaemia.
Topics: Blood Glucose; Gastric Bypass; Glucagon; Humans; Hypoglycemia; Incretins; Insulin; Postprandial Period; Vagus Nerve | 2019 |
Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis.
Topics: Ampulla of Vater; Bariatric Surgery; Bile; Bile Acids and Salts; Bilirubin; Blood Glucose; Cholestasis, Extrahepatic; Diabetes Mellitus, Type 2; Duodenal Neoplasms; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Pancreaticoduodenectomy; Postprandial Period | 2019 |
Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly.
Topics: Acromegaly; Adult; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Hyperglycemia; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Prospective Studies; Receptors, Gastrointestinal Hormone | 2019 |
Dysregulated insulin in pancreatic insufficient cystic fibrosis with post-prandial hypoglycemia.
Topics: Adolescent; Area Under Curve; Blood Glucose; C-Peptide; Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemia; Incretins; Insulin; Insulin Secretion; Male; Young Adult | 2020 |
Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; C-Peptide; Calcinosis; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Fibrosis; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Pancreatitis, Chronic; Time Factors; Young Adult | 2021 |
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.
Topics: Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucose; Humans; Incretins; Receptors, G-Protein-Coupled; Receptors, Gastrointestinal Hormone | 2021 |
Whey protein preload enhances the active GLP-1 response and reduces circulating glucose in women with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Analysis of Variance; Area Under Curve; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Dietary Proteins; Dietary Supplements; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hyperglycemia; Incretins; Insulin; Polycystic Ovary Syndrome; Postprandial Period; Whey Proteins; Young Adult | 2021 |
The sugar-responsive enteroendocrine neuropeptide F regulates lipid metabolism through glucagon-like and insulin-like hormones in Drosophila melanogaster.
Topics: Animals; Animals, Genetically Modified; Drosophila melanogaster; Enteroendocrine Cells; Female; Glucagon; Glucagon-Like Peptide 1; Hormones; Humans; Hypoglycemia; Incretins; Insulin; Insulin Secretion; Lipid Metabolism; Mutation; Neuropeptides; Receptors, Neuropeptide; Sugars | 2021 |
Impact of the different biliopancreatic limb length on diabetes and incretin hormone secretion following distal gastrectomy in gastric cancer patients.
Topics: Aged; Anastomosis, Roux-en-Y; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gastrectomy; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Male; Middle Aged; Postoperative Period; Prospective Studies; Stomach Neoplasms; Treatment Outcome | 2021 |
Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Sorbitol | 2022 |
The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzylidene Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Nicotinic Agonists; Pyridines; Sitagliptin Phosphate; Tyrosine | 2022 |
Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Incretins; Insulin; Insulin Resistance; Meals; Pituitary ACTH Hypersecretion; Somatostatin | 2022 |
Comparison of Hormonal Response to a Mixed-Meal Challenge in Hypoglycemia After Sleeve Gastrectomy vs Gastric Bypass.
Topics: Blood Glucose; Female; Gastrectomy; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemia; Incretins; Insulin; Male; Middle Aged; Obesity, Morbid | 2022 |
The Cytoskeletal Transport Protein, Secretagogin, Is Essential for Diurnal Glucagon-like Peptide-1 Secretion in Mice.
Topics: Actins; Animals; Carrier Proteins; Glucagon; Glucagon-Like Peptide 1; Glucose; Incretins; Insulin; Mice; Proteasome Endopeptidase Complex; Secretagogins | 2022 |
Metabolic Dysregulation in Adult Survivors of Pediatric Hematopoietic Stem Cell Transplantation: The Role of Incretins.
Topics: Adult; Blood Glucose; Child; Cross-Sectional Studies; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Hematopoietic Stem Cell Transplantation; Humans; Incretins; Insulin; Male; Metabolic Syndrome; Survivors | 2023 |
SMALL INTESTINAL L CELL DENSITY IN PATIENTS WITH SEVERE OBESITY AFTER ROUX-EN-Y GASTRIC BYPASS.
Topics: Anastomosis, Roux-en-Y; Diabetes Mellitus, Type 2; Enteroendocrine Cells; Gastric Bypass; Glucagon; Humans; Incretins; Obesity, Morbid; Treatment Outcome | 2022 |
Multi-action Secretagogin Controls Circadian Glucagon-Like Peptide-1 Secretion.
Topics: Animals; Carrier Proteins; Glucagon; Glucagon-Like Peptide 1; Incretins; Mice; Secretagogins | 2022 |
Implication of sugar, protein and incretins in excessive glucagon secretion in type 2 diabetes after mixed meals.
Topics: Blood Glucose; Caseins; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Meals; Obesity; Sucrose; Sugars | 2023 |
Alterations of adipokines, pancreatic hormones and incretins in acute and convalescent COVID-19 children.
Topics: Adipokines; Adiponectin; C-Peptide; Child; Complement Factor D; COVID-19; Cytokines; Diabetes Mellitus, Type 2; Ghrelin; Glucagon; Granulocyte Colony-Stimulating Factor; Humans; Incretins; Interleukin-12; Interleukin-17; Interleukin-6; Leptin; Pancreatic Hormones; SARS-CoV-2; Tumor Necrosis Factor-alpha | 2023 |
Designer GLP1 poly-agonist peptides in the management of diabesity.
Topics: Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins | 2023 |
Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea-treated KCNJ11 neonatal diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Infant, Newborn; Insulin | 2023 |
Glucagon as the First Incretin: Objects (in the Rearview Mirror) Are Closer Than They Appear.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Humans; Incretins; Insulin | 2023 |